Insider trade

Director sold ~$703K of MRNA shares in the open market

Traded Dec 11, 2025 · Filed Dec 15, 2025

ModernaMRNA

~$703K
Reported value · 24K sh @ $29.49: 3,924
Holds after · shares reported: +585.8%
stock since the trade · S&P 500 +12.4%, $29.63 → $203.21 on Oct 5

Why it stands out

A board member of Moderna sold $703K of Moderna shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 11, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 15, 2025

DirectorIndirect holding$500K–$1M

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$703,306

Shares × reported transaction price

Timing vs results

35 days after results of Nov 6, 2025, 32 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $29.63 on Dec 11, 2025, 33% above its 52-week low and 38% below its high, after a 20% rise over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $47.53 (Jan 7, 2025), 29% of the way up, from 250 adjusted closes. 30 trading days earlier: $24.70 on Oct 29, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+8.0%	+1.3%	+6.7%
30 days	+31.7%	+2.0%	+29.7%
90 days	+78.3%	−1.4%	+79.8%
180 days	+74.4%	+11.2%	+63.2%

Past results only. Not a forecast.

Source receipt

Record ID: 0001193125-25-318567
Filed / recorded: Dec 15, 2025, 2:00 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Moderna, Inc.
Issuer CIK: 1682852
Ticker: MRNA
Reporting person: Noubar Afeyan
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Dec 11, 2025
Transaction code: S
Shares / units: 23,853
Price per share: $29.49
Acquired / disposed: Disposed (D)
Shares owned after: 3,924
Ownership form: Indirect — By Flagship Pioneering, Inc.
Amendment: No

Footnotes from the filing

The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.